Find clinics referencing tesamorelin in hormone optimisation and metabolic protocols. Compare verified providers, prescribing context, and clinical supervision. This page is informational and does not diagnose, prescribe, or recommend therapies.
Looking for clinics by city? Explore peptide clinics in Miami , Los Angeles, and New York to compare verified providers by treatment focus.
Recovery peptide users often compare BPC-157 and TB-500, while metabolic health users usually cross-reference semaglutide.
Growth-hormone users often move between peptide research and provider discovery. Use the matching tool to narrow the right clinic path, or browse peptide clinics directly if you want to compare locations first.
Tesamorelin pages tend to sit further down the buying journey, when users are comparing more specialist hormone and metabolic providers. Clear screening and monitoring matter more than bold marketing language.
This page is useful for people researching clinician-led hormone or body-composition pathways and comparing clinics that discuss secretagogue-related treatment models.
Pricing should be interpreted in the context of medical oversight. Higher numbers may reflect diagnostics and physician review, while lower-touch offers may provide little beyond access.
Tesamorelin is a growth hormone-releasing hormone analogue that appears in some hormone, metabolic, and body-composition clinic discussions. In directory terms, it usually signals a more specialist or medically supervised pathway rather than a broad wellness offer.
At a high level, tesamorelin interacts with signaling related to endogenous growth hormone release. For patients comparing clinics, what matters most is not mechanism jargon but whether the provider explains why tesamorelin is being considered, what testing is used, and how outcomes are monitored.
Tesamorelin pricing can vary materially depending on whether the clinic offers a narrow prescribing model or a broader hormone-optimisation programme. Compare the monthly figure with what is included in diagnostics, clinician review, and ongoing follow-up. See the peptide therapy cost guide.
Tesamorelin belongs in a supervised medical discussion, not a generic wellness funnel. A credible clinic should explain suitability, contraindications, and how treatment response would be monitored.
Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.
Yes, but narrowly. Tesamorelin has been FDA-approved since 2010 under the brand name Egrifta, solely to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and it remains the only treatment approved in the US for that indication; a longer-acting formulation, EGRIFTA WR, was approved in 2025. Approval attaches to that specific indication, so the body-composition and anti-aging uses clinics more often discuss fall outside it and would be off-label.
It is not licensed here. Tesamorelin holds no MHRA or EMA marketing authorisation for any indication — the European application was withdrawn by its sponsor in 2012 and never resubmitted — so the US Egrifta approval does not carry across. Any UK clinical use sits under unlicensed-medicine rules, typically as a named-patient import, with full responsibility resting on the prescribing clinician.
Yes. Tesamorelin is named on the WADA prohibited list under growth hormone releasing factors, alongside sermorelin and CJC-1295, and is prohibited at all times rather than in competition only. Its FDA approval does not change that, because the class is defined by mechanism rather than by approval status. Any athlete subject to testing should treat it as banned.
No. Tesamorelin is a growth hormone-releasing hormone analogue, which prompts the body to release its own growth hormone rather than supplying growth hormone directly. Clinics sometimes present that as a more physiological approach, but it remains a prescription-only medicine that requires proper medical supervision.
Its approved use is reducing visceral abdominal fat in adults with HIV-associated lipodystrophy, where pooled phase III data showed roughly a 15% reduction in visceral fat against placebo over 26 weeks. In directory terms, though, it usually appears in hormone, metabolic and body-composition clinic discussions among people without that condition — which is off-label, and where the evidence is considerably more limited.
No. Peptide Clinic Finder is an informational directory. We do not sell tesamorelin, provide medical advice, or recommend its use, and this page gives no dosing or administration guidance — we help you compare how clinics position and supervise treatments so you can make an informed decision with a licensed clinician.
Related comparisons: Sermorelin vs Tesamorelin.
Next step
If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.
Move from peptide research into clinic comparisons, guides, and matching.
Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.
Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programmes first, while others want a faster route into matched options or local clinic discovery.
Next step
Move from peptide research into real provider comparison by checking city pages, cost context, and related treatment comparisons. Clinics vary more by oversight and programme structure than by peptide name alone.
For clinics
Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.